Oppenheimer analyst Jason Helfstein increased the price target for Amazon.com (NASDAQ:AMZN) to $260, up from the previous $230, while maintaining an Outperform rating on the stock. The adjustment ...
About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...